Abstract:Current immune checkpoint blockade therapy (ICBT) predominantly targets T cells to harness the antitumor effects of adaptive immune system. However, the effectiveness of ICBT is reduced by immunosuppressive innate myeloid cells in tumor microenvironments (TMEs). Toll‐like receptor 7/8 agonists (TLR7/8a) are often used to address this problem because they can reprogram myeloid‐derived suppressor cells (MDSCs) and tumor‐associated M2 macrophages, and boost dendritic cell (DC)‐based T‐cell generation; however, the systemic toxicity of TLR7/8a limits its clinical translation. Here, to address this limitation and utilize the effectiveness of TLR7/8a, we suggested a programmed two‐step activation strategy via Antibody‐Trojan Immune Converter Conjugates (ATICC) that specifically targeted myeloid cells by anti‐SIRPα followed by reactivation of transiently inactivated Trojan TLR7/8a after antibody‐mediated endocytosis. The ATICC blocked the CD47‐SIRPα ("don't eat me" signal), enhanced phagocytosis, reprogrammed M2 macrophages and MDSCs, and increased cross‐presentation by DCs, resulting in antigen‐specific CD8+ T‐cell generation in tumor‐draining lymph nodes and TME while minimizing systemic toxicity. The local or systemic administration of ATICC improved ICBT responsiveness through reprogramming of the immunosuppressive TME, increased infiltration of antigen‐specific CD8+ T cells, and antibody‐dependent cellular phagocytosis. Our results highlighted the programmed and targeted immunomodulation via ATICC could enhance cancer immunotherapy with minimized systemic toxicities. This article is protected by copyright. All rights reserved

Switchable immune modulator for tumor-specific activation of anticancer immunity

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Site-specific nanoswitch circumventing immune resistance via activating TLR and inhibiting PD-L1/PD-1 axis

Tumor‐Selective Activation of Toll‐Like Receptor 7/8 Agonist Nano‐Immunomodulator Generates Safe Anti‐Tumor Immune Responses Upon Systemic Administration

A size-switchable nanocluster remodels the immunosuppressive microenvironment of tumor and tumor-draining lymph nodes for improved cancer immunotherapy

Polysulfonium: Unveiling a Bioactive Polymer to Induce Immunogenic Cell Death for Anticancer Therapy

Stimuli-Responsive Polymersomes: Reshaping the Immunosuppressive Tumor Microenvironment

Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager

Multifunctional Nanomodulators Regulate Multiple Pathways to Enhance Antitumor Immunity

Hypoxia-Inducible Factor-1α-Activated Protein Switch Based on Allosteric Self-Splicing Reduces Nonspecific Cytotoxicity of Pharmaceutical Drugs

Versatile strategy for controlling the specificity and activity of engineered T cells

Functionally Masked Antibody to Uncouple Immune-Related Toxicities in Checkpoint Blockade Cancer Therapy

Polymeric nanocarrier via metabolism regulation mediates immunogenic cell death with spatiotemporal orchestration for cancer immunotherapy

Small-molecule Modulators of Tumor Immune Microenvironment

Organic Semiconducting Sono-Metallo-Detonated Immunobombs for Ultrasensitized Domestication of Immunosuppressive Cells

Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors (adv. Sci. 12/2023)

Activatable cancer sono‐immunotherapy using semiconducting polymer nanobodies

A pH-responsive polymersome depleting regulatory T cells and blocking A2A receptor for cancer immunotherapy

Bioconjugated Antibody‐Trojan Immune Converter Enhance Cancer Immunotherapy with Minimized Toxicity by Programmed Two‐step Immunomodulation of Myeloid Cells

A Tumor-Responsive Nanostrategy for Reducing the Risk of Immunotherapy-Related Myocarditis

Tumor‐Microenvironment‐Activatable Polymer Nano‐Immunomodulator for Precision Cancer Photoimmunotherapy